In 2019, BioNTech, the most expensive biotech company in the US, was listed on the NASDAQ. Today it announced that it has filed a registration statement on the form, F-1, and the US Securities and Exchange Commission to issue 13,200,000 US common stock (ADS) to the public. BioNTech also intends to grant the underwriters a 30-day option to purchase an additional 1,980,000 ADS. The initial public offering price per ADS is expected to be between $18.00 and $20.00, and BioNTech expects to raise about $250 million at the midpoint of the range, raising a maximum of $304 million. BioNTech has applied to list its American Depositary Receipts on the NASDAQ Global Select Market under the symbol "BNTX". At the highest price range of the proposed initial public offering, BioNTech's valuation can reach 4.6 billion US dollars, almost double the valuation in January. The CBV Alliance database of the drug circle found that the highest financing of the US stocks in 2019 so far has been raised by BridgeBio. The market value of the $348 million issue was only $2,048 million. BioNTech said that in addition to potential investments in complementary technologies and products, the proceeds will be used for general corporate purposes. Last year, BioNTech signed a $425 million agreement with Pfizer to develop a more effective flu vaccine, and Pfizer also acquired a small stake in the biotech company. As the largest private biopharmaceutical company in Europe, BioNTech received a total of 695 million US dollars in financing in 2018 (A$270 million/$11.99 in A18 and a $325 million/$18.10 in B20 in July 2019). . Since its inception, it has received $1.3 billion in funding through financing and cooperation. Investment institutions include Strüngmann Family Office, MIG Fonds, Salvia GmbH, Redmile Group, Janus Henderson Investors, Invus, Fidelity Management & Research Company, Different European family offices, Mirae Asset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management .
Founded in 2008, BioNTech is headquartered in Munich, Germany, and has research and development in San Diego, USA. It was founded by the founders of science, Prof. Ugur Sahin, MD, Prof. Christoph Huber, MD and Özlem Türeci, MD, and was acquired by the Strüngmann family. AT Impf, and the MIG Fonds Fund completed a €150 million seed round investment. Andreas and Thomas Strüngmann are serial entrepreneurs. The German generic drug company Hexal and the US generic drug company Eon Labs were acquired by Novartis for $8.3 billion. The two then set up family funds to focus on investing in health care. Strüngmann family office and MIG have invested in, created and sold many biotech companies such as SuppreMol, Ganymed AG, CorImmun, Sivantos (former Siemens hearing aid business), Press Ganey (surgical instrument company) and Apceth (cell therapy company). At the time of the establishment of BioNTech, Dr. Sahin and Dr. Türeci were the Chief Scientific Officer and Chief Medical Officer of Ganymed, respectively. The company was founded in 2001 to develop monoclonal antibodies (zolbetuximab) for CLDN18.2, Anstel in 2016. Acquisition of Ganymed, Germany, with a down payment of US$460 million and a potential mileage of US$960 million.
The goal is that each cancer patient's tumor is unique, and in order to effectively address this challenge, a personalized treatment must be created for each patient. To achieve this vision, the company has combined decades of pioneering research in immunology, cutting-edge treatment platforms, and a range of patient profiling and bioinformatics tools to develop personalized immunotherapies for cancer and other diseases. Take advantage of powerful new therapeutic mechanisms and use a variety of biological targets to harness the power of each patient's immune system to address the unique molecular characteristics of each patient's underlying disease.
BioNTech and partners have advanced the development of more than 20 candidate products, 8 of which have entered 9 ongoing clinical trials. Although BioNTech believes that the methods used are broadly applicable to many therapeutic areas, the highest priority program to date has focused on oncology, and BioNTech has treated more than 250 patients in 17 tumor types. BioNTech's immunotherapeutic drug categories include messenger ribonucleic acid or mRNA therapies, therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators. BioNTech's candidate products cover cancer, infectious diseases and rare diseases.
BioNTech has assembled a team of 1,179 employees and has partnered with seven pharmaceutical partners including Genentech, Sanofi, Genmab, Genevant Sciences, Eli Lilly, Bayer and Pfizer. BioNTech has built a comprehensive, highly automated, on-demand manufacturing capability that complements the company's development of personalized immunotherapy.
The use of mRNA technology for the preparation of vaccines, treatment of tumors, etc. is not a patent of BioNTech. Moderna of the United States focuses on the development of mRNA vaccines for infectious diseases, tumors, immune diseases and rare diseases, and completed the $604 million IPO in December 2018, becoming 2018. The largest fundraising amount of US biotech stocks, the issue price of 23 US dollars per share, and the market value of the listed market is 7.5 billion US dollars. It was also founded in 2009, with 680 employees at the time of listing. At the time of writing, Moderna had a market capitalization of only $5.4 billion.
There is no doubt that Europe's strongest mRNA biotechnology company will be listed on the US stock market and Moderna will be the highest, who is the most expensive biotechnology company listed in the past two years, we are looking forward to ~
